StageZero Life Sciences Ltd.
SZLSF
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.94M
Close$
Share Statistics
| Market cap | $4.94 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.11 |
| Beta | 0.34 |
| Outstanding Shares | 123,532,948 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$3.49 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$3.49 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About StageZero Life Sciences Ltd.
40 employees
CEO: James R. Howard-Tripp StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of disea...